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Abstract: Malaria remains the most serious parasitic diseases affecting humans in the world today, resulting in 1-2 mil-
lion fatalities each year. Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the predominant causative agents. 
Both are responsible for widespread mortality and morbidity and are a serious socio-economic burden, especially for 
countries in the developing world. One of the most important defences against malaria has been the use of chemothera-
peutic drugs (e.g. chloroquine, artemisinins, pyrimethamine) but these have mainly been found by serendipity. Their 
mechanisms was not understood at the time of their discovery and, even today, are still not unequivocal. For many of 
these compounds, the parasite is now resistant and, hence, there is an urgent need to develop new therapeutic drugs di-
rected to validated targets. One metabolic pathway crucial for the survival and replication and survival of the parasite is 
the synthesis of the purine nucleoside monophosphates essential for the production of DNA/RNA molecules. A key en-
zyme in this pathway is the 6-oxopurine phosphoribosyltransferase (PRTase). The focus of this review is on the identifica-
tion and characterization of inhibitors of the enzymes from both Pf and Pv as antimalarial drug leads. The acyclic nucleo-
side phosphonates (ANPs) appear to be excellent candidates because they are good inhibitors of the two Plasmodium en-
zymes, can be selective compared to the human enzyme, can arrest parasitemia in cell based assays, have low cytotoxicity 
to the human host cell and, because of their stable carbon-phosphorous bond, are stable within the cell.  
Keywords: Malaria, acyclic nucleoside phosphonates, hypoxanthine guanine phosphoribosyl transferase. 
INTRODUCTION 
 Plasmodium remains the deadliest parasite to humans on 
the planet [1]. It is a member of the phylum Apicomplexa, 
which is characterized by the presence of a unique organelle 
known as the apicoplast. The function of this organelle is 
speculative but it may be involved in any or all of lipid me-
tabolism, heme and amino acid biosynthesis [2,3]. There are 
four major species of Plasmodium that infect humans and 
result in the symptoms of malaria: malariae, ovale, falcipa-
rum and vivax. In addition, P. knowlesi a common form of 
primate malaria has also been reported in humans [4] and is 
now an emerging strain of some concern [5,6]. Of these five 
strains, P. falciparum (Pf) and P. vivax (Pv) are the most 
lethal and widespread. Pv and Pf differ in their geographical 
distributions with Pv occurring widely in the tropics and 
extending throughout India, Eastern China, as far north as 
Korea and throughout Asia reaching as far as the Mediterra-
nean Sea [7]. Pv is found as far south as Papua New Guinea 
and is prevalent in Central and South America. Pf, by com-
parison, exists predominantly in Africa though it is also 
found in the tropical and sub-tropical areas of Central and 
South America and South East Asia [8]. 
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 Pf is reputed to infect around 500 million people per year 
while at least two billion live in areas at risk [7]. Over 70% 
of Pf infections occur in the African region, while another 
25% are in South East Asia. These estimated numbers are 
not all that different for Pv, with at least two billion people 
also exposed to this strain of Plasmodium. Because of the 
difficulty in obtaining precise figures, the number of those 
who develop clinical symptoms due to Pv can only be esti-
mated but is around 70-390 million with >80% occurring in 
South and Southeast Asia [7].  
 The clinical symptoms of Pv and Pf are different in a 
number of respects. While Pf is the most lethal, Pv is respon-
sible for serious illness with recurring bouts of fever that 
occurs over a long term. This is due to the fact that Pv has 
the capability to lie dormant in the liver of the host. Nonethe-
less, both strains are responsible for a huge burden of human 
suffering and have a serious socio-economic impact in the 
countries where they are prevalent. 
 A number of approaches, both alone and in combination, 
have been adopted to try to combat malaria; these include 
vector control, drug therapy, indoor residual spraying, mos-
quito nets and bedclothes, vaccines, and improved education 
for those who live in areas of risk, but the problem still re-
mains a major challenge for the medical community today. 
Vector control (i.e. disruption of the life cycle of the 
Anopheles mosquito) has proved only partially preventative 
and has not been sufficient to eliminate the parasite. Bed-
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netting and other such methods have been introduced as 
stop-gap measures and, though helpful in the short term, 
have not been proven to be effective long term solutions [9]. 
Vaccines, a hoped for cure, offers promise but despite enor-
mous efforts, none have yet made it to the pharmacy. Re-
views on the status of vector control [10,11] and vaccine 
development [12-14] have recently been published and will 
not be discussed further. In the remainder of this review, the 
focus is on the discovery and development of therapeutic 
drugs to treat malaria (and other) parasitic diseases.  
 The use of drugs to treat malaria dates back to ~1640 
when the bark of the cinchona tree was found to be effective 
in alleviating the symptoms of the disease. However, the 
mechanism of action was not understood and this remained 
so until 1820 when the active ingredient was identified as the 
alkaloid, quinine [15]. It has been suggested that quinine 
could lay claim to being responsible for relieving more hu-
man suffering than any other drug in history. However, it 
was not until 1881 that the causative agent for malaria was 
discovered when Charles Laveran visualized the parasite in 
blood. Seventeen years then elapsed before the method of 
transmission was identified as occurring via the Anopheles 
mosquito. New chemotherauptics were developed as an off-
shoot of attempts to produce a synthetic version of quinine. 
These included 8–aminoquinoline which was subsequently 
developed into primaquine and mepacrine [15]. Chloroquine 
was first synthesised in the Bayer laboratories in 1934 but it 
was not introduced as an antimalarial drug until 1947 be-
cause of its potential toxic side effects. Sadly, drugs of the 
20th century developed by the western-world such as quina-
crine, choloroquine and primaquine are today failing to re-
duce the spread of the disease due to the emergence of 
strains of Plasmodium that have developed resistance against 
these therapeutic drugs [9]. Even today, for many of the cur-
rently used drugs, the mechanism of action is still the subject 
of conjecture. For example, the action of quinine, chloro-
quine and its derivatives is poorly understood, but it is be-
lieved they work by preventing polymerization of the toxic 
heme [16], which is released as a byproduct of hemoglobin 
digestion. Resistance by the parasite to chloroquine arises 
due to mutations in the sequence of the chloriquine resis-
tance transporter [17].  
 Several other antimalarial drugs have been discovered 
and developed over the years. These are shown in Fig. (1). 
Most if not all of these have problems associated with their 
use (i.e. resistance [9] and cost-effectiveness), further high-
lighting the need to discover new antimalarial targets and 
therapeutic agents. Artemisinin, a natural product from the 
leaves of the herb, sweet wormwood, Artemisia annua, was 
isolated in the 1960s. The leaves of such plants had been in 
use in China for more than a thousand years as a treatment 
for malaria but, just like the bark from the cinchona tree, the 
active ingredient was not known nor was its mechanism of 
action proposed until recent times. However, as with most 
drugs, problems of expense, unknown side effects and in-
creasing resistance must now be overcome.  
 Today, with the sequencing of the Pv [18] and Pf ge-
nomes [19] and through the use of advanced scientific ap-
proaches such as the screening of large chemical libraries 
[20], we are now in an unprecedented position to design and 
develop drugs to specifically target and treat malaria. Ad-
vances in structural biology have facilitated the determina-
tion of the three-dimensional structure of proteins essential 
for the life cycle of the parasite. This is a significant factor in 
allowing us to understand the mechanisms by which drugs 
interact with their target and how resistance can develop. 
Based on these advances in knowledge and technologies, it is 
envisaged that new generations of therapeutic agents will not 
only be effective in the short term but have the potential to 
eradicate malaria.  
 The main focus in new drug development against malaria 
has, to date, centered on Pf. Pv has been sometimes been 
referred to as the neglected disease, not because of its devas-
tating effect on the health of the population, but because it 
was reputed not to be as lethal as Pf [21]. However, with 
increasing global awareness, attention is now turning to the 
very serious health and socio-economic burden caused by 
this species of the disease. In the development of new anti-
malarials consideration needs to be given to drugs that can 
control both Pf and Pv. This aspect is an important focus of 
the current review. Several other factors that are specific to 
the development of antimalarials also need to be considered. 
These include the need for drugs to: 
1) be cost effective, as those regions most highly affected 
are predominantly in developing countries; 
2) target proteins that are specific to the parasite’s survival 
but are non-toxic to the host cell; 
3) target proteins that would be difficult for the parasite to 
mutate without compromising its own existence; 
4) be able to cross the membranes of both the erythrocyte 
(where the red blood cell stage is targeted) and the para-
site; and 
5) be stable within the cell to be effective. 
 For optimal drug discovery, differences between the me-
tabolism of the parasite and its host cell should be exploited. 
Adopting this rationale minimizes the difficulty of finding a 
drug which binds tightly and specifically to a parasite protein 
but much less so to the homologous human protein. This 
approach is being exploited to discover inhibitors that target 
a broad range of proteins, and especially those found in the 
apicoplast [22], an organelle unique to the parasite. An im-
portant metabolic difference between the human host and the 
parasite lies in their ability to synthesise the purine nucleo-
side monophosphates essential for DNA/RNA production. 
Like all protozoan parasites, Pf and Pv are auxotrophic for 
the purine ring and depend on the 6-oxopurine phosphoribo-
syltransferase (PRTase) for the synthesis of the nucleoside 
monophosphates. Humans, however, are able to make purine 
rings from small molecules and thus are not totally depend-
ent on the salvage pathway. The precise role of 6-oxopurine 
PRTase in metabolism will be discussed in the next section 
and is one of the focuses of this review.  
 The parasite needs to synthesise large amounts of nucleic 
acids within the 48-hour life of the erythrocytic stage of their 
development, when the parasites grow and divide rapidly. 
After multiplying within an erythrocyte, the parasite ruptures 
the cell wall of the erythrocyte releasing toxic metabolites 
into the host. Thus, drugs targeted at disrupting the machin-
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ery of cell replication will not only exert its effects on the 
health of those infected but will also help to eradicate the 
parasite since it will not be available for further infection of 
the red blood cells nor for transmission to the Anopheles 
mosquito. 
 6-Oxopurine PRTase can be targeted in two ways for 
drug discovery. The first is to use the catalytic properties of 
the enzyme to convert exogeneous base analogs to mononu-
cleotides toxic to the parasite while the second is direct inhi-
bition of the enzyme itself [22-24]. 6-Oxopurine PRTases 
exist in all organisms and have common structural and cata-
lytic features but there are significant differences in substrate 
specificity, catalytic efficiency and importance in the life 
cycle of the particular organism. It is proposed that inhibitors 
of the malarial enzymes could also be inhibitors of the 6-
oxopurine PRTases found in other disease causing protozoan 
parasites or bacteria. In the case of bacterial infection, it has 
been suggested that 6-oxopurine PRTase inhibitors have 
potential to treat stomach ulcers that result from infection by 













































Fig. (1). Drugs that have been used to combat malaria. aThe quinolines are thought to inhibit the polymerization of heme though other targets 
have been postulated e.g. tyrosine kinase, haemoglobin degrading proteases, DNA and phospholipases [16]. bPrimaquine, also a quinoline, 
should not be administered to patients with a glucose-6-phosphate dehydrogenase or NADH methemoglobin reductase deficiency [65]. cHa-
lofantrine may have a similar mechanism of action to the quinolines [66]. dAtovaquone is a broad spectrum drug that inhibits mitochondrial 
electron transport at the cytochrome bc1 complex and collapses mitochondrial membrane potential [67]. eArtemisinins have a highly reactive 
endoperoxide moiety that is thought to be critical for their mode of action [68,69]. fClindamycin inhibits bacterial protein synthesis by stop-
ping ribosomal translocation by binding to the 28S rRNA. It is derivative of the natural antibiotic, lincomycin [70]. gDoxycycline impairs the 
progeny of the apicoplast genes resulting in their abnormal cell division [71]. hSulfadoxin and Pyrimethamine are used in combination to 
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tors have the potential to be broad-spectrum antimicrobial 
drugs.  
 For the remainder of this review, the focus is on the as-
sessment of the 6-oxopurine PRTases as targets for the de-
velopment of antimalarial drugs directed against Pf and Pv. 
Here we will discuss; (i) the metabolic pathways available to 
Pf and Pv to produce the essential purine nucleotides; (ii) 
what is known about the overall chemistry of the reaction 
catalysed by the 6-oxopurine PRTases; (iii) the evidence that 
suggests 6-oxopurine PRTase is an excellent target for anti-
malarial drug discovery; (iv) the discovery of substrate and 
product analogs of 6-oxopurine PRTases that arrest para-
sitemia in cell culture; and (v) a comparison of the three-
dimensional structures of several 6-oxopurine PRTases and 
the implications for drug discovery. 
1.1. The Metabolic Pathway Available in Pf and Pv for 
the Synthesis of the Purine Nucleoside Monophosphates 
 A difference in metabolism between the host cell and 
protozoan parasites is their ability to synthesise the purine 
nucleoside monophosphates. Mammals possess two path-
ways to produce these metabolites: de novo from small 
molecules and salvage of preformed purine bases. Humans 
rely on both pathways but, although inherited mutations in 
the gene coding for HGPRT can have deleterious symptoms, 
deficiency by up to 97% in activity can readily be treated by 
allopurinol [24]. This is because the clinical symptom due to 
the partial loss of HGPRT activity is the over-production of 
uric acid. Allopurinol (1,5-dihydro-4H-pyrazolo[3,4-
d]pyrimidin-4-one) is an analog of Hx in which the nitrogen 
in the 7-position is replaced by carbon and the carbon in the 
8-position is replaced by nitrogen. This compound was 
originally developed at Burroughs Wellcome in the 1940s 
and led to the synthesis of drugs such as acyclovir, 
trimethoprim and the early antineoplastic compounds, 
thioguanidine and 6-mercaptopurine (6-MP). Allopurinol is 
not only an inhibitor of xanthine oxidase but it is also a sub-
strate. After administration, it is rapidly converted to 
oxipurinol (pyrazolo[3,4-d]pyrimidine 1-N-ribonucleotide). 
Oxipurinol has a longer half-life than allopurinol itself and it 
is also an inhibitor of xanthine oxidase. The basic effect of 
the administration of allopurinol is, therefore, to decrease the 
concentration of uric acid produced from the 6-oxopurine 
bases, hypoxanthine and xanthine, by xanthine oxidase. One 
of the problems in drug design is the possibility of toxic 
side-effects to the host, but the wealth of data on deficient 
human HGPRT suggests that a weak to moderate inhibitor of 
human HGPRT should not prove to be toxic to the host.  
 All protozoan parasites studied to date are auxotrophic 
for the purine base and have to rely on the transport of pre-
formed metabolites from the host. In Pf, there are three key 
enzymes involved in the salvage of purine nucleobases and 
nucleosides transported from the host cell Fig. (2). These are 
adenosine deaminase (ADA), purine nucleoside phosphory-

















Fig. (2). The metabolic route for purine nucleic acid synthesis in Pf (and Pv). ADA, adenosine deaminase; PNP, purine nucleoside phos-
phorylase; (1) adenylsuccinate synthase; (2); IMP dehydrogenase; (3) adenylsuccinate lyase; and (4) GMP synthase. 
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bosyltransferase (HGXPRT) (i.e. 6-oxopurine PRTase). 
ADA converts adenosine transported across the parasite 
membrane to inosine, which is converted to hypoxanthine 
(Hx) by PNP. HGXPRT then catalyses the formation of IMP 
from Hx. HGXPRT also synthesises IMP directly from Hx 
transported across the parasite cell membrane Fig. (2). Hy-
poxanthine is a crucial source of the purines within the para-
site and is the usual nutritional additive to the media in Pf 
grown in cell culture. The external concentration is usually 
around 370 μM. One piece of evidence that supports the im-
portance of Hx in the purine metabolism of Pf is the fact that 
supplementation of media with 100-400 μM Hx results in a 
3-4 fold increase in parasite yield [25]. The importance of 
Hx as a central metabolite on which Pf depends for survival 
is further demonstrated by the fact that increasing the con-
centration of xanthine oxidase in the media [26] (which ef-
fectively reduces the amount of Hx available to the parasite 
by converting it to uric acid) inhibits the growth of Pf. This 
inhibition can be reversed by adding excess Hx back to the 
media [26]. 
 The specific activity of the 6-oxopurine PRTase for hy-
poxanthine in Pf is of the order of 60-fold higher than that of 
human HGPRT in the erythrocyte emphasizing its impor-
tance in the parasite’s metabolism. The high concentration of 
HGXPRT in Pf cells in culture has also been demonstrated 
by confocal microscopy Fig. (3). 
 Gero et al. [27] were the first to demonstrate that nucleo-
sides are actively transported into the parasite via a mem-
brane protein. Sequencing of the Pf genome has revealed 
four proteins that could be responsible for the transport of 
purine nucleobases and nucleosides into the parasite. These 
have been identified as PfNT1, 2, 3 and 4 [28-30]. However, 
to date, only PfNT1 has been characterized [29,31,32]. The 
concentration of the nucleobases and nucleosides in the host 
cell that are available to the parasite for their source of 
purines are given in Table 1. 
 The high levels of hypoxanthine in red blood cells further 
suggests that it is a primary source of nucleoside monophos-
phates for the invading parasite (Table 1). Adenosine is pre-
sent in high concentrations in the red blood cell and this can 
be converted to AMP by adenosine kinase (AK), which by 
deamination would give IMP. However, sequencing of the Pf 
genome shows that there is no cDNA coding for AK in the 
parasite and thus the sole route for IMP synthesis is via the 
three enzymes; ADA, PNP and HGXPRT [33]. There was a 
possibility that a second purine salvage enzyme, adenine 
PRTase (APRT), could provide a route for the synthesis of 
AMP. Reyes et al. [34] did measure activity of this enzyme 
in isolated parasites but the level was around 1500-fold less 
than for HGPRT suggesting that its role in parasite metabo-
lism was minor. Later evidence, however, revealed that there 
is no gene coding for APRT in P. falciparum [33] and the 
activity measured was probably due to contamination with 
the red blood cell APRT. Thus, the pivotal enzyme in pro-
ducing the nucleoside monophosphates is HGPRT and the 
central metabolite for their production is IMP.  
Table 1. The Concentration of Purine Nucleobases and Pur-
ine Nucleosides in Human Red Blood Cells 
Metabolite Concentration (μM) 
Hypoxanthine 8.2 ± 1.3 [73]   
Xanthine 2.5 ± 0.6 [73] 
Adenine 0.3 ± 0.15 [73]   
Adenosine 0.6 ± 0.2 [73] 
 
 It has recently been reported that, contrary to the assump-
tion that anionic, phosphorylated metabolites are unable to 
be transported across the cell membrane, AMP is able to 
cross into Pf from the host cell [35]. Thus far, a membrane 
transporter has not been identified though is has been estab-
lished that PfNT1 is unable to transport AMP [35]. The ob-
servation that AMP is transported is based on two lines of 
evidence. Firstly, inhibitors of the parasite’s PNP and ADA 
result in a reduction in cell growth which can be rescued by 
high concentrations of adenosine but this rescue is signifi-
cantly reduced if the human AK enzyme is inhibited as AK 
provides the source of AMP in the erythrocyte [35]. The 
second piece of evidence in support of AMP transport is the 
appearance of radiolabelled Hx within the parasite cell after 
exogenous supply of radiolabelled AMP [35]. This is pre-
sumably by the action of two enzymes, AMP deaminase 
which converts AMP to IMP and then by HGXPRT which 










Fig. (3). Localisation of PfHGXPRT in parasite cells grown in erythrocyte culture. A. Non-stained region showing the rupture of a red blood 
cell by parasites. B. Fluorescence image of the same region incubated with an antibody against PfHGXPRT and visualized with a secondary 
antiserum conjugated to FITC.  
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2090    Current Topics in Medicinal Chemistry, 2011, Vol. 11, No. 16 de Jersey
 
et al. 
1.2. The Reaction Catalysed by the 6-Oxopurine PRTases 
 The 6-oxopurine PRTases belong to a group of ten en-
zymes which are responsible for the synthesis of purine nu-
cleotides, pyrimidine nucleotides, NAD and, in bacteria and 
lower eukaryotes, histidine and tryptophan [36]. The reaction 
catalysed by this enzyme is shown in Fig. (4). For catalysis 
to occur a divalent metal ion must be present and this is usu-
ally Mg2+ in vivo though other divalent metal ions such as 
Mn2+ are also effective substitutes [37]. The mechanism of 
action of human HGPRT is ordered: PRib-PP.Mg2+ binds 
first followed by the purine base [38]. Pyrophosphate then 
dissociates from the complex and the nucleoside monophos-
phate is released in the rate-limiting step. For the enzymes 
from Tritrichomonas foetus [39], Leishmania donovani [40], 
Schistosoma mansoni [41] and Trypanosoma cruzi [42], this 
mechanism is also sequential and it is therefore likely that all 
the 6-oxopurine PRTases operate in a similar fashion.  
 It has been proposed that the mechanism could proceed 
by an SN2-type displacement due to the inversion of configu-
ration at the anomeric carbon of PRib-PP. However, evi-
dence strongly supports a two-step SN1-mechanism [43] with 
the formation of an unstable intermediate ribooxycarbenium 
ion Fig. (5).  
 A common feature in the structures of the 6-oxopurine 
PRTases is the presence of a large flexible loop consisting of 
between 10-20 amino acid residues (depending on the par-
ticular enzyme involved) that closes over the active site dur-
ing the catalytic reaction. It has been hypothesised that the 
role of this loop is to help stabilise the transition state and to 
protect the bound PRib-PP.Mg2+ from hydrolysis by bulk 
solvent [44]. The role of this loop in structure-based drug 
design is discussed later.  
1.3. A Comparison of the Kinetic Properties of 6-
Oxopurine PRTases from Human, P. Falciparum, P. 
Vivax and E. Coli Cells 
 The 6-oxopurine PRTases from different organisms can 
be classified based on their different specificities for the 
three naturally-occurring purine bases, guanine, hypoxan-
thine and xanthine (Table 2). Thus, while some enzymes can 
use all three bases (though with different catalytic efficien-
cies), some are able to use only two while others have a dis-
tinct preference for one base alone (Table 2). 
 Many organisms possess only one 6-oxopurine PRTase 
and this appears to be sufficient to synthesise all the essential 
nucleoside monophosphates that they require for survival. 
These organisms include humans, Pf and Pv. However, T. 
gondii, L. donavani and E. coli possess two 6-oxopurine 
PRTases with differing base specificities. Though there are 
distinct differences in the preference for the 6-oxopurine 
bases, all these 6-oxopurine PRTases contain a common fea-
ture, which is their ability to bind the first substrate to enter 
the active site, PRib-PP Mg2+. Because of the relatively 
small differences in the Km values for PRib-PP between all 
these enzymes (~25-60 μM; Table 3 and between 25-32 μM 
for the enzymes from L. donavani ,G. lamblia, T. gondii 
[42,45,46], it could be assumed that PRib-PP binds in a 
highly conserved region in their structures. A comparison of 
the sequences of the enzymes in this region (Section 1.6) 
confirms this. A comparison of the kinetic constants of the 6-
oxopurine PRTases from human, Plasmodium and E. coli 










Fig. (5). Structure of the transition state in the reaction catalysed by 
the 6-oxopurine PRTases. R is –NH2 (guanine) or –H (hypoxan-
thine). 
 
 One of the most striking differences between the 6-
oxopurine PRTases is in their kcat values for their respective 
nucleobase substrates. The bacterial enzymes are the most 
efficient having values around 4-7 times higher for the pre-
ferred purine base compared to that for the human enzyme. 
In comparing human HGPRT with PfHGXPRT and 
PvHGPRT, this ratio is between 50-90 and 20-34, respec-
tively. An explanation for these differences could be that 
parasite enzymes do not need to have a high turnover rate as 
these are present in much higher levels in Plasmodium com-
pared to human erythrocytes where HGPRT is only ex-









Fig. (4). The reactions catalysed by the 6-oxopurine PRTases. The naturally occurring purine bases are guanine (R is –NH2), hypoxanthine 
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Table 2. Purine Base Specificity for the 6-Oxopurine 
PRTases from Different Organisms
a 
Name Source 
HGXPRT T. gondii [74,75], T. foetus [39], P. falciparum [76] 
HGPRT Mammals [77], L. donovani [78], P. vivax [47] 
HPRT E. coli [79, 80] 
XGPRT L. donovani [40,78], E. coli [79,80], T. gondii [74,75] 
GPRT G. lamblia [81,82] 
aThe abbreviations indicate base specificity 
 Both Pf and Pv enzymes bind Hx more tightly than gua-
nine as would be expected if hypoxanthine is the primary 
source of nucleoside monophosphates, whether this is by 
direct transport or via ADA and PNP Fig. (2). However, 
though PfHGXPRT distinguishes between guanine and hy-
poxanthine in terms of catalytic efficiency (kcat/Km), 
PvHGPRT uses both these bases equally well. In compari-
son, the human enzyme prefers guanine as its substrate. The 
Pf genome is 80% AT compared with Pv which is 55% AT. 
Thus, Pv has a higher requirement for guanine mononucleo-
tides than does Pf. 
 Another difference between the Pf and Pv enzymes is 
their ability to use xanthine [47]. This is surprising given that 
these two enzymes have 77% amino acid sequence identity 
(see Section 1.6). Pf may have evolved to use xanthine dur-
ing its life-cycle in the mosquito. However, Pv does not have 
this requirement. Whether this ability to use xanthine occur-
red later or earlier in the evolutionary tree is unknown, but 
an understanding of this difference in metabolism between 
the two strains warrants further investigation. 
 There are other differences between the human, Pf and 
Pv enzymes and one of these is in the Ki values for the 
mononucleotide product. PvHGPRT binds GMP and IMP 
more weakly than the Pf or human enzymes. For PvHGPRT, 
the Ki for IMP is 62 μM and for GMP, this value is 26.1 μM 
[47]. PfHGXPRT binds these compounds more tightly, with 
Ki values of 3.6 ± 1 μM and 10 ± 2 μM, respectively. The 
human enzyme is more similar to PfHGXPRT in this respect 
(Ki for IMP is 5.4 ± 1.2 μM and, for GMP, 5.8 ± 0.2 μM). E. 
Table 3. Kinetic Constants for Human, Plasmodium and E. coli 6–Oxopurine PRTases 
Organism Substrate kca (s
-1
) Km (μM) kcat/Km (μM-1s-1) 
Hx 5.2 ± 0.4 3.4 ± 1.0 1.5 
Guanine  8.2 ± 0.6 1.9 ± 0.4 4.3 
Human HGPRTa 
Xanthine 
 PRib-PP (Hx) 
NSd  NS 
59.6 ± 6 
?5 
Hx 0.33 ± 0.08 0.07 ± 0.03 4.3 
Guanine 0.66 ± 0.07 0.83 ± 0.5 0.8 
Xanthine 3.3 ± 0.2 189 ± 18 0.02 
PfHGXPRTa 
PRib-PP (Hx)  23 ± 4  
Hx 0.74 ± 0.01 0.93 ± 0.12 0.8 
Guanine 1.7 ± 0.03 1.9 ± 0.4 0.9 
Xanthine   ? 5 
PvHGPRTb 
PRib-PP (Hx)  42 ± 1  
Hx 13.7 ± 1.3 90.8 ± 11.3 0.02 
Guanine 34.1 ± 2.7 2.6 ± 0.7 13.1 
Xanthine 37.5 ± 0.7 30.5 ± 2.6 1.2 
E. coli XGPRTc 
PRib-PP (G) 28.2 ± 0.8 32.4 ± 3.2 0.87 
Hx 59.0 ± 3.5 12.5 ± 2.4 4.9 
Guanine 10.2 ± 0.7 294 ± 20 0.03 
Xanthine 0.008 ± 0.001 25 ± 6.1 0.0003 
E. coli HPRTc 
PRib-PP (Hx) 66.9 ± 1.2 45.9 ± 2.5 1.46 
aKeough et al.,[76]  bKeough et al.,[47]  cGuddat et al.,[80]  dNS = not a substrate.  
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coli XGPRT binds GMP tightly with a Ki value of 4.6 ± 0.6 μM though HPRT binds the product of the reaction very 
weakly and has a Ki for IMP of 247 ± 55 μM (unpublished 
data).  
1.4. Base Analogs as Potential Drug Leads 
 The use of base analogs which could be good substrates 
for the malarial 6-oxopurine PRTases but weak for the hu-
man enzyme has been considered as a potential pathway to 
drug development. Such purine base analogs would be con-
verted by the 6-oxopurine PRTase to the corresponding 
mononucleotide which, after incorporation into nucleic ac-
ids, would be toxic to the cells. This is a similar mechanism 
of action to that proposed for the anti-cancer agent, 6-
mercaptopurine [48].  
 A comparison of the kinetic constants for a number of 
purine base analogs is given in Table 4. Some of these purine 
substrate analogs discriminate between the human and Pf 
enzymes with relative catalytic efficiency up to 370 in fa-
vour of the Pf enzyme (8-azahypoxanthine) but only 30-fold 
for the PvHGPRT in comparison with human HGPRT (6-
thioguanine) [49]. These differences in base specificity pro-
vide evidence that, although catalysing a similar reaction, 
differences in the active site exist between the three enzymes 
which can be exploited for drug design. In addition, the 
study demonstrates that the purine binding site can accept 
molecules other than the three naturally occurring 6-
oxopurines.  
 Further studies have shown that these compounds are 
effective in arresting cell growth of the Pf parasite in culture, 
with IC50 values as low as 1 ?M (Table 5). At this time, Pv 
cannot be maintained in culture, so Pf is the only model for 
testing the effectiveness of such compounds in cell culture. 
For two compounds tested in P. berghei ANKA in CD1 mice 
(mice are not infected by falciparum or vivax), it was shown 
that 6-mercaptopurine reduced parasitemia by 47% and 8-
azaguanine by 32% [47]. This appears to be a reflection of 
the ability of the 6-oxopurine PRTase in P. berghei to con-
vert these bases into toxic metabolites. 
Table 4. Comparison of the Catalytic Efficiencies (kcat/Km) of the Purine base Analogs for Human Pf and Pv 6-Oxopurine PRTases
a,b
 
kcat/Km (μM-1 s-1)  
Purine base Analog 
Hu Pf Pv 
6-mercaptopurine 2.0 20 0.5 
6-thioguanine 0.05 1.0 1.4 
6-thioxanthine ?4 0.005 NDc 
2-amino-6-chloropurine ?0.00013 0.007 ?0.0001 
8-azahypoxanthine 0.001 0.37 0.003 
8-azaguanine 0.005 0.4 0.004 
allopurinol 0.003 0.06 0.0006 
a Keough, et al. [49],  bKeough, et al. [47] cND = not determined 
 
Table 5. Effect of Purine base Analogs on the uptake of [
3
H]hypoxanthine into Parasite Nucleic Acids and on the Growth of P. 







H]hypoxanthine Cell growth 
2-thioxanthine NI NI 
6-mercaptopurine 1.3± 0.3 2 
6-thioguanine 21.3±6 10 
6-thioxanthine NI NI 
2-amino-6-chloropurine 67±36 10 
8-azahypoxanthine 90 ±11 38 
8-azaguanine 6.6±1.9 18 
allopurinol ?150 Weak or none 
aKeough et al. [49] 
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1.5. Inhibitors of the Malarial Enzymes and Comparison 
with the Human Enzyme 
 The first inhibitors with low Ki values for both human 
HGPRT and PfHGXPRT were the immucillin 5?-phosphates 
synthesized by Schramm and his colleagues [50]. Their 
structure is based on mimicing the transition state of the 
catalytic reaction of the 6-oxopurine PRTases Fig. (5). These 
elegantly designed compounds, the (1S)-1-(9-deazaguanin-9-
yl)-1,4-dideoxy-1,4-imino-D-ribitol 5?-phosphates (immucil-
lin 5´-phosphates) Fig. (6), bind to the human and Pf en-
zymes with Ki
* values of 1-4 nM [50]. These compounds 
only bind tightly in the presence of PPi and Mg
2+. An X-ray 
crystal structure of this complex shows the interactions that 
occur between the inhibitor and amino acid side chains and 
backbone atoms present in the active site [51]. One charac-
teristic of these compounds is that, on binding, they cause 
the flexible loop to close firmly over the active site [51]. 










Fig. (6). Structure of the immucillin 5´-phosphates. R is –NH2 
(guanine) or –H (hypoxanthine). 
 
 A second class of compounds that inhibit the human, Pf 
and Pv enzymes is the acyclic nucleoside monophosphonates 
(ANPs). Their structure is based on those of the antiviral 
drugs such as adefovir [52], which target the DNA polym-
erase of the virus to prevent replication. These molecules 
possess excellent pharmacokinetic properties and they have 
low cytotoxicity toward human cells [53]. Thus, it was hy-
pothesized that such compounds with a 6-oxopurine base 
could inhibit the parasite 6-oxopurine PRTases and prove 
efficacious as antimalarial drugs Fig. (7), Tables 6 and 7.  
 The ANPs were subsequently tested for their ability to 
inhibit the growth of Pf in cell culture. The original observa-
tion that ANPs could be effective against Pf was first made 
in 1999 [54] and showed that (S)-9-(3-hydroxy-2-phos-
phonomethoxypropyl)guanine inhibited the growth of Pf in 
cell culture with an IC50 value of 4.3 ± 0.9 μM. However, the 
mechanism of action was unknown at that time. The most 
likely target for these compounds is identified as HGXPRT 
which now makes possible the development of new com-
pounds by rational structure-based design approaches.  
 Currently synthesised ANPs do not bind to the 6-
oxopurine PRTases as tightly as the immucillin 5´-
phosphates. However, as drug leads they have four strengths: 
1) They can exhibit selectivity for the Pf and Pv enzymes 
over the human counterpart (Table 6); 
2) They can arrest the growth of Pf in cell culture and have 
IC50 values as low as 100 nM, showing that they can be 
transported across the red blood cell and Pf membranes 
though the mechanism of transport has yet to be defined;  
3) Many have low cytotoxicity in human A549 and U251 
cell lines suggesting that they have minimal, if any, in-
hibitory effect on cellular enzymes (including human 
HGPRT);  
4) They possess a stable carbon-phosphorus bond between 
the phosphonate group and the linker to the purine base. 
Thus, these molecules are not susceptible to hydrolysis 


















Fig. (7). Structures of the phosphonate moieties (Table 7) and the D-ribose 5´-phosphate of the purine nucleoside monophosphates. 
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1.6. Comparison of the Amino Acid Sequences between 
the Human, Pf and Pv Enzymes and the Location of the 
Amino Acid Substitutions of PvHGPRT in the Structure 
of PfHGXPRT 
 One of the focuses of this review has been the identifica-
tion of ANPs as antimalarial drug leads. ANPs, depending 
on the base attached and the chemical characteristics of the 
linker between the base and the phosphonate group, can be 
effective inhibitors of the human, Pf and Pv 6-oxopurine 
PRTases, though with a range of Ki and selectivity values 
(Tables 6 and 7). Furthermore, differences in catalytic effi-
ciencies for the naturally occurring and exogenous bases 
between these three enzymes also demonstrate that these 
enzymes are not identical (Tables 4 and 5). The differences 
in the catalytic properties and inhibition by the ANPs can 
only be attributed to the changes in the amino acid sequences 
and three-dimensional structures of the enzymes. A compari-
son of the overall sequences of the Pf and Pv 6-oxopurine 
PRTases shows that they have 77% amino acid sequence 
identity Fig. (8). However, when compared with the human 
enzyme, the identities for PfHGXPRT and for PvHGPRT are 
lower being 45% and 39%, respectively. Thus, overall, there 
is a significant level of sequence variability across the three 
enzymes. Based on the three-dimensional structures that 
have been determined for the 6-oxopurine PRTases (Table 
8), the binding sites for the purine base, 5´-phosphate, pyro-
phosphate and Mg2+ have been established. The sequence 
alignment of the human, Pv and Pf enzymes Fig. (8) shows 
that the residues that make up these sites are largely con-
served across these three enzymes though there are some 
subtle differences in sequence when the surrounding areas 
are considered. The regions of largest sequence difference 
between the three enzymes are in the N-terminus (residues 
14-20), the C-terminus (residues 224-232), residues 96-106 
(the mobile loop) and residues 121-124. The amino acid sub-
stitutions between the two Plasmodium enzymes occur pri-
marily in the flexible loops Fig. (9) surrounding the active 
site. The amino acid changes in the core structure are mainly 
conservative and are not expected to affect the overall fold. It 
is therefore not immediately obvious as to the molecular 
basis for the difference in specificities and specific activities 
of the three enzymes. We discuss this in terms of our know-
ledge of the 3-D structures of 6-oxopurine PRTases in the 
section below.  
Table 6. Inhibition of the Pf and Human 6-Oxopurine PRTases by ANPs
a 
Ki (μM) 
Base Phosphonate Tail 
PfHGXPRT Human HGPRT 
Guanine Ribose-5´-phosphate 10 ± 2 5.8 ± 0.2 
Hypoxanthine Ribose-5´-phosphate 3.6 ± 1 5.4 ± 1.2 
Guanine PEE 0.1 ± 0.02 1.0 ± 0.50 
Hypoxanthine PEE 0.3 ± 0.04 3.6 ± 0.2 
Guanine PME 1.6 ± 0.2 29 ± 4 
8-Azaguanine PME 3 ± 0.4 175 ± 20 
8-Hydroxyguanine PME 1.2 ± 0.3 68 ± 6 
8-Bromoguanine PME 10 ± 4 >400 
Guanine (R,S)-HPMP 0.6 ± 0.2 5.9 ± 0.4 
8-Bromoguanine (S)-PMP 11 ± 4 >300 
Guanine Cyclic-(S)-HPMP 8 ± 1 90 ± 10 
Guanine Cyclic-(R)-HPMP 1 ± 0.2 19 ± 5 
aKeough et al. [22] 
 
Table 7. Inhibition of PvHGPRT by Acyclic Nucleoside Phosphonates
a 
Base Phosphonate Ki (μM) 
8-azaguanine PEE 3.3 ± 0.7 
guanine 4'-Me-PEE 6.4 ± 1.5 
2-amino-6-bromopurine PEE 2.9 ± 0.8 
aKeough et al. [47] 



















Fig. (8). Alignment of the amino acid sequences of PvHGPRT, PfHGXPRT and human HGPRT. *indicates identity between the Pf and Pv 
enzymes. Red indicates the differences in the sequence between the two parasite enzymes and black those amino acid substitutions which are 
conservative. Green denotes the residues that interact with the purine base (??. The residues which bind to Mg2+ are colored in red while the 
residues which hold the PPi moiety in place are in purple (+). The 5?-phosphate binding residues are designated by a red box and or a white 
star (tyrosine). 
 
Table 8. Crystal Structures of the 6-Oxopurine PRTases 
Source Ligand and Reference Resolution (Å) 
Human 
Human HGPRT free [55] 1.9 
Human HGPRT PRib-PP.HPP.Mg2+ [83] 2.7 
Human HGPRT immGP.PPi. Mg
2+ [51] 2.0 
Human HGPRT (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)guanine [22] 2.6 
Human HGPRT 9-(2-phosphonoethoxyethyl)hypoxanthine [22] 2.8 
Human HGPRT 9-(2-phosphonoethoxyethyl)guanine [22] 2.6 
Human HGPRT GMP [56] 2.5 
Protozoan parasites 
PfHGXPRT immHP.PPi. Mg
2+ [57] 2.0 
T. gondii HGPRT GMP [45] 1.7 
T. gondii HGPRT IMP [45] 1.9 
T. gondii HGPRT XMP.PPi.Mg
2+ [46] 1.6 
T. gondii HGPRT 9-deazaguanine,PRib-PP.Mg2+ [74] 1.1 
T. cruzi HPRT free [86] 1.4 
T. cruzi HPRT ternary complex [84] 1.8 
T. cruzi HPRT IMP [85] 2.3 
?
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(Table 8) contd… 
Source Ligand and Reference Resolution (Å) 
T. cruzi K68R HPRT IMP [85] 2.7 
T. cruzi K68R HPRT 7-hydroxy-pyrazolo[4,3-D]pyrimidine.PRib-PP.Mg2+ [85] 2.0 
G. lamblia GPRT immGP.PPi.Mg
2+ [86] 1.8 
G. lamblia GPRT immGP [86] 1.8 
L. tarentolae HGPRT GMP [87] 2.1 
Bacteria  
E. coli XGPRT free [88] 1.8 
E. coli XGPRT cPRib-PP.guanine.Mg2+ [88] 2.0 
E. coli XGPRT cPRib-PP.xanthine [88] 2.0 
E. coli XGPRT GMP [89] 2.0 
E. coli HPRT free [80] 2.9 
E. coli HPRT IMP [80] 2.8 














Fig. (9). The active site and surrounding regions of PfHGXPRT. 
Crystal structure of PfHGXPRT in complex with Mg2+-
immucillinHP-5?-phosphate and pyrophosphate. Amino acid resi-
dues that differ in the Pf and Pv enzymes are colored dark blue. 
Side-chains are displayed as stick models for residues that differ 
between the two enzymes and that are close to active site. Mg2+ 
ions are drawn as purple spheres, immucillinHP-5?-phosphate and 
pyrophosphate as green and red stick models, respectively. The 
mobile loop is coloured cyan. 
 
1.7. Crystal Structures of the 6-Oxopurine PRTases 
 The crystal structures of a number of the 6-oxopurine 
PRTases from different organisms have been determined 
(Table 8). However, only the structures for PfHGXPRT, 
Giardia lamblia GPRT and human HGPRT have been de-
termined in the presence of inhibitors. All the other struc-
tures are either unliganded or in complex with substrates or 
products. Structures of human HGPRT have been the most 
widely studied and reveal the movements of the flexible 
loops that occur during the catalytic cycle (Table 8).  
 The 6-oxopurine PRTases have a number of structural 
features that contribute to the binding of the substrates and 
the products. These include the purine base, 5?-phosphate 
and pyrophosphate binding sites and the presence of a large 
flexible (mobile) loop, which closes over the active site dur-
ing catalysis shielding it from solvent. For human HGPRT, 
in the unliganded form or in the presence of the mononucleo-
tide product of the reaction, this loop is open and disordered 
[55,56]. However, in complex with the transition state in-
hibitor, immucillinGP.Mg2+ and PPi, the loop is firmly 
closed and ordered and has the structure of two anti-parallel 
?-strands [51]. This is a similar conformation as to when 
immucillinHP.Mg2+ and PPi binds to PfHGXPRT [57]. 
 Three structures of human HGPRT in complex with in-
hibitors have been determined. These are with the ANPs, 
(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, 9-
(2-phosphonoethoxyethyl)hypoxanthine and 9-(2-
phosphonoethoxyethyl)guanine [22]. In all of these struc-
tures, the mobile loop is mainly random coil but is partially 
closed over the active site. The movement of this loop is 
depicted in Fig. (10). The closure of this loop is therefore 
likely to be an important contributing factor in the binding 
affinity and selectivity of 6-oxopurine PRTase inhibitors. 
 The pyrophosphate binding site is a small flexible loop 
consisting of four amino acids (Table 9). In human HGPRT, 
replacement of LKGG by LKEG, LKRG, LKGV or LKGR 
results in a complete absence of activity (Lesch-Nyhan syn-
drome), emphasising its overall importance. In this region, 
the Pf and Pv enzymes differ by one residue (LKGS) com-
pared with the human enzyme. This is, therefore, a potential 
site for an inhibitor to impart selectivity for the parasite en-
zymes over the human equivalent. The immucillin 5?-



















Fig. (10). Crystal structures of PfHGXPRT and human HGPRT. (a) Connolly surface of the active site of PfHGXPRT showing the location 
of immucillinHP-5?-phosphate, PPi and Mg2+. (b) The interactions of PPi and Mg2+ with active site residues in PfHGXPRT. (c) The subunit 
structure of human HGPRT showing the movement of the large (mobile) loop which occurs during catalysis. (d) The interactions between the 
ANP inhibitor, PEEG, and active site residues in human HGPRT. 
 
Table 9. The Amino Acid Sequence in the Pyrophosphate Binding Loop in Different 6-Oxopurine PRTases 
Enzyme PPi Loop Sequence Km (PPi) 
Human LKGG 25 
S. mansoni LKGG 25 
Pf, Pv, T. gondii LKGS NKa 
T. foetus LTGA 165 
E. coli SRGG NKa 
G. lamblia LTGA 424 
aNK = not known 
phosphates only bind in the presence of pyrophosphate and 
magnesium ions. Thus, occupancy of the pyrophosphate 
binding site appears to be another contributing factor leading 
to an increased binding affinity of the immucillin 5?-
phosphates to these enzymes. 
 The 5?-phosphate binding pocket Fig. (10), Table 9; 
TGKTL for Pf and Pv), is a highly conserved region of the 
6-oxopurine PRTases. In human HGPRT, this region, like 
the pyrophosphate and the large mobile loop is also flexible. 
In the free human HGPRT crystal structure, the distance be-
tween T138 and T141 is only 4.3 Å [55]. This distance ex-
pands to 7.8 Å when the 5?-phosphate group is bound, 
thereby preparing the active site for the purine base to enter 
[56]. This binding pocket anchors the phosphate group of the 
immucillin 5?-phosphates and the phosphonate moiety of the 
ANPs in position contributing to their affinity. 
 The residues involved in binding the purine base are 
D148, K176, F197 and V198 in PfHGXPRT Fig. (10). These 
are conserved in the human and Pv enzymes. D148 binds to 
the N7 nitrogen, K176 binds to the 6-oxo group and confers 
specificity for the 6-oxopurines over the 6-aminopurines, 
while F197 forms a pi bond with the purine ring and the car-
bonyl oxygen of V198 can form hydrogen bond(s) to the N1 
nitrogen and the R substituent Fig. (10) of the C2 carbon of 
the purine ring. The structural contribution to the differences 
in affinity for the purine bases between the human and Pf 
and Pv enzymes is unclear. This can be attributed to the 
present lack of structures of the parasite enzymes. The only 
direct comparison between the Pf and human enzymes are 
the complexes with the immucillin 5?-phosphates. In these 
structures, the amino acid side chains and the backbone 
atoms which place the base in position are in completely 
conserved locations. PfHGXPRT was solved only with its 
preferred base, Hx, attached to the immucillin 5´-phosphate 
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(Tables 3 and 8) while human HGPRT was also only solved 
with its preferred base, guanine, attached. If structures were 
available with alternate bases, this would aid in the under-
standing of the purine base specificity for these enzymes. 
1.8. Inhibitors of the 6-Oxopurine PRTases from other 
Protozoan Parasites 
 There are a number of other protozoan parasites that in-
fect humans and animals leading to severely debilitating and 
potentially life-threatening diseases. Amongst the most seri-
ous and widespread of these parasites are Leishmania dono-
vani, Giardia lamblia, Trypanosoma cruzi, Toxoplasma 
gondi and Tritrichomonas foetus. The first four of these re-
sult in infection to humans while the last of these is prevalent 
in cattle and therefore pose a serious risk to the meat and 
dairy industries. While there are differences in the metabo-
lism between these parasites, they share a commonality in 
that they are all auxotrophic for the purine ring. Thus, the 6-
oxopurine PRTases have been studied in these parasites with 
a view to developing chemotherapeutic agents that targets 
these enzymes. 
 Through broad screening approaches, using both chemi-
cal and computational libraries, a number of molecules have 
been discovered as inhibitors of protozoan parasite 6-
oxopurine PRTases. These have targeted the enzymes from 
T. cruzi, T. foetus and G. lamblia. 





































aFreymann et al. [58] 
 Four compounds as potential inhibitors (Tables 10 and 
11) of T. cruzi HPRT were identified using a modified ver-
sion of the program, DOCK [58]. These results came from 
the in silico screening of over 34 million compounds. Their 
Ki values for the enzymes from T. cruzi, human and S. ty-
phimurium were determined (Table 11), and for T. cruzi 
HPRT, these values ranged from 0.5 μM to 11.8 μM and the 
selectivity over the human counterpart ranged between 2.5-
32. Three of these compounds (Compound numbers 1159, 
141430 and 156385) were also found to inhibit the growth of 
the parasite in infected mouse macrophages. The addition of 
increased levels of Hx to the media (up to 300 μM from 2.5 
μM) reversed this inhibition, strongly suggesting that the 
target was indeed HPRT. The chrysene compound (32980), 
though a good inhibitor of T. cruzi HPRT with a Ki value of 
0.5 ± 0.06 μM, was the only compound that did not inhibit 
parasite growth. This was a disappointing finding as it was 
selective for the parasite enzyme, having a Ki value of 16 ± 
9.2 μM (32-fold difference in selectivity). Subsequently, 
chrysene derivatives were further investigated as potential 
anti-parasitic drugs. These compounds are very hydrophobic 
and, though exhibiting Ki values between 0.5-9 μM (Table 
12), they also did not inhibit the growth of the parasite [59]. 
These molecules contain a cluster of four aromatic rings 
(Table 12). It is likely that a portion of these would occupy 
or partially occupy the purine binding site. The aromatic 
amino acid that covers the purine binding site (F197 in 
PfHGXPRT; F164 in T. cruzi HPRT) would potentially form 
a pi-stacking arrangement with the aromatic rings from these 
inhibitors. Unfortunately, these molecules have proved inef-
fective in vivo. The reason for their failure is attributed to 
their inability to be transported through the plasma mem-
brane, even though they appear to be quite hydrophobic [59]. 
Nonetheless, a Ki value of 0.5 μM for the best of these in-
hibitors for T. cruzi HPRT is encouraging and suggests that 
derivatives of this class could be useful as drug leads if a 
delivery system can be developed.  
Table 11. Kinetic Inhibition Constants for Lead Inhibitors of 
T. cruzi HPRTa  
Ki (μM) 
Inhibitor 
T. cruzi human S. typhimurium 
1159 2.2 ± 0.2 5.4 ± 1.1 - 
32980 0.5 ± 0.06 16.0 ± 9.2 >>25 
141430 11.8 ± 0.8 28.8 ± 4.7 48.1 ± 1.8 
156385 2.0 ± 0.2 10.9 ± 1.6 13.9 ± 0.7 
aFreymann et al. [58] 
 The compound 4-[N-(3,4-dichlorophenyl)carbamoyl] 
phthalic anhydride called TF1; Fig. (11) was identified by 
computational docking as a potential inhibitor for T. foetus 
HGXPRT [60]. Kinetic studies confirmed that TF1 is a com-
petitive inhibitor of guanine and GMP with Ki values of 13 μM and 10 μM, respectively. TF1 does not inhibit human 
HGPRT even at concentrations of 1 mM, so is highly selec-
tive for the parasite enzyme. TF1 inhibited the growth of T. 
foetus in culture with an EC50 of 40 μM [61]. This corre-
sponded to a decrease in the amount of exogenous guanine 
incorporated into the parasite’s nucleic acids which could be 
reversed by supplementation of the media with excess hy-
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Structure of the R group Ki (μM) 
H 8.9 ± 0.2 
F 2.8 ± 0.2 
 
0.6 ± 0.1 
 
6.7 ± 0.6 
 
0.5 ± 0.06 
aMedrano et al. [59] 
 
Fig. (11). Structure of 4-[N-(3,4-dichlorophenyl)carbamoyl] 
phthalic anhydride (TF1). 
 
poxanthine or guanine [60]. Thus, these data provide further 
evidence that compounds which block the purine salvage 
pathway is detrimental to the life cycle of such protozoan 
parasites. Based on this structure, a virtual library of substi-
tuted 4-phthalimidocarboxanilines was screened. This led to 
the development of TF2 [(4?-phthalimido)carboxamido-3-(4-
bromobenzyloxy)benzene] Fig. (12) [61]. The effect of these 
substitutions was to reduce the Ki with respect to guanine to 
0.49 μM (26-fold lower). Though this compound is a good 
inhibitor of the parasite enzyme, the selectivity in favour of 
this enzyme compared to human HGPRT was reduced to 30. 
This compound also arrested parasitemia with an ED50 of 2.8 μM. This reduction in the ED50 value compared with TF1 
(14-fold) is consistent with the tighter binding to T. foetus 
HGPRT. As with TF1, the effect on the growth of the para-
site could be reversed by the addition of exogenous Hx. TF2 
is not a competitive inhibitor with PRib-PP as predicted 
from the docking studies which argued for non-overlapping 
binding sites with the substrate.  
 
Fig. (12). Structure of [(4?-phthalimido)carboxamido-3-(4-
bromobenzyloxy)benzene] (TF2). 
 
 A structural library using derivatives based on 
phthalimide chemistry was screened against G. lamblia 
GPRT [62]. From more than 300 molecules tested, two were 
found to inhibit G. lamblia GPRT with Ki values around 24 μM Fig. (13). However, these compounds were not highly 
selective for the parasite enzyme compared with human 
HGPRT with IC50 ratios between the two enzymes of only 1- 
to 2-fold.  
 
Fig. (13). Structures of inhibitors of G. lamblia GPRT. 
 
 Bisphosphonates which are analogs of the pyrophosphate 
product of the reaction have been found to inhibit T. cruzi 
HPRT [63]. Their structures are given in Fig. (14). These 
compounds are competitive inhibitors of pyrophosphate with 
Ki values for T. cruzi HPRT of 188.6 ± 11.8 μM (ALN), 
126.0 ± 5.0 μM (OPD), 50.6 ± 3.7 μM (PAM) and 23.2 ± 2.3 
μM (RIS). These compounds could potentially inhibit many 
other enzymes involved in organic and pyrophosphate reac-
tions such as farnesyl-pyrophosphate synthase, squalene syn-
thase or proton-pumping pyrophosphatases. Thus their mode 
of action at the cellular level is unclear. However, these mol-
ecules do appear to be capable of inhibiting the 6-oxopurine 
PRTases by blocking the pyrophosphate binding site. 
 








 A comparison of the sequences of Pf, Pv, T. cruzi, T. 
gondii, T. foetus and L. donavani 6-oxopurine PRTases 
shows that, although they can have overall identities as low 
as 22%, the residues that make up their active site (i.e. those 
highlighted in Fig. (9) are almost 100% conserved across 
these six enzymes. The only variations that exist across these 
enzymes are conserved differences at the 5´-phosphate bind-
ing site (i.e. residue 150 (PfHGXPRT numbering) can be 
S/T, 151 A/G, and 152 I/K/L/F) and F197, the aromatic resi-
due that covers the purine binding pocket which is trypto-
phan in the T. gondii enzyme but phenylalanine in all of the 
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others. It is therefore proposed that drugs directed toward the 
Plasmodium 6-oxopurine PRTases should also be leads in 
drug discovery for other protozoan parasitic diseases and 
vice-versa. Furthermore, this review clearly demonstrates 
that potent inhibitors of parasitic 6-oxopurine PRTases are 
not necessarily inhibitors of the human enzyme and, thus, 
design of drugs targeted specifically to the enzymes from 
protozoan parasites is feasible. 
CONCLUSION 
 Due to the widespread emergence of drug resistant 
strains of the malarial parasites, it is imperative that new 
drugs are discovered and become commercially available or 
can be donated to developing countries through charitable 
organizations such as the Bill and Melinda Gates Foundation 
or the World Health Organization (WHO). This review es-
tablishes the purine salvage pathway as a drug target because 
it is essential for the survival and replication of the parasite. 
Drugs that target the 6-oxopurine PRTase alone should be 
very effective, but a cocktail that can successfully inhibit 
ADA and PNP [64] (two other important enzymes in the 
production of the nucleoside monophosphates) should make 
it virtually impossible for the parasite to mutate and survive. 
ANPs are particularly attractive lead compounds because not 
only are they selective for the Plasmodium enzymes over the 
human counterpart but they have been found to exhibit ex-
cellent pharmacokinetic properties and, because of the car-
bon-phosphorous bond, are stable within the cell. 
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ABBREVIATIONS 
Pf = Plasmodium falciparum 
Pv = Plasmodium vivax 
HGPRT = hypoxanthine-guanine phosphoribosyltrans-
ferase 
HGXPRT = hypoxanthine-guanine-xanthine phosphori-
bosyltransferase 
PRTase = phosphoribosyltransferase 
PRib-PP = 5-phospho-?-D-ribosyl-1-pyrophosphate 





PEEG = 9-(2-phosphonoethoxyethyl)guanine 
IMP = inosine 5´-monophosphate 
Hx = hypoxanthine 
PNP = purine nucleoside phosphorylase 
ADA = adenosine deaminase  
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